Global Blood Therapeutics Statistics
Share Statistics
Global Blood Therapeutics has 0
shares outstanding. The number of shares has increased by 4.55%
in one year.
| Shares Outstanding | n/a |
| Shares Change (YoY) | 4.55% |
| Shares Change (QoQ) | 1.01% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -6.08 and the forward
PE ratio is null.
Global Blood Therapeutics's PEG ratio is
-0.31.
| PE Ratio | -6.08 |
| Forward PE | n/a |
| PS Ratio | 9.46 |
| Forward PS | n/a |
| PB Ratio | 9.38 |
| P/FCF Ratio | -7.08 |
| PEG Ratio | -0.31 |
Financial Ratio HistoryEnterprise Valuation
Global Blood Therapeutics has an Enterprise Value (EV) of 1.82B.
| EV / Sales | 9.33 |
| EV / EBITDA | -6.52 |
| EV / EBIT | -7.07 |
| EV / FCF | -6.99 |
Financial Position
The company has a current ratio of 9.11,
with a Debt / Equity ratio of 3.36.
| Current Ratio | 9.11 |
| Quick Ratio | 8.45 |
| Debt / Equity | 3.36 |
| Debt / EBITDA | -2.37 |
| Debt / FCF | -2.54 |
| Interest Coverage | -18.57 |
Financial Efficiency
Return on Equity is -154.32% and Return on Invested Capital is -33.6%.
| Return on Equity | -154.32% |
| Return on Assets | -32.27% |
| Return on Invested Capital | -33.6% |
| Revenue Per Employee | $426,146.61 |
| Profits Per Employee | $-663,218.82 |
| Employee Count | 457 |
| Asset Turnover | 0.21 |
| Inventory Turnover | 0.06 |
Taxes
| Income Tax | 477K |
| Effective Tax Rate | -0.16% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is 0.46, so Global Blood Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.46 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 62.32 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 77.11 |
| Average Volume (20 Days) | n/a |
Income Statement
In the last 12 months, Global Blood Therapeutics had revenue of 194.75M
and earned -303.09M
in profits. Earnings per share was -4.82.
| Revenue | 194.75M |
| Gross Profit | 191.43M |
| Operating Income | -287.15M |
| Net Income | -303.09M |
| EBITDA | -278.53M |
| EBIT | -286.6M |
| Earnings Per Share (EPS) | -4.82 |
Full Income StatementBalance Sheet
The company has 684.72M in cash and 659.62M in
debt, giving a net cash position of 25.1M.
| Cash & Cash Equivalents | 684.72M |
| Total Debt | 659.62M |
| Net Cash | 25.1M |
| Retained Earnings | -1.29B |
| Total Assets | n/a |
| Working Capital | n/a |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -256.81M
and capital expenditures -3.23M, giving a free cash flow of -260.05M.
| Operating Cash Flow | -256.81M |
| Capital Expenditures | -3.23M |
| Free Cash Flow | -260.05M |
| FCF Per Share | -4.13 |
Full Cash Flow StatementMargins
Gross margin is 98.3%, with operating and profit margins of -147.44% and -155.63%.
| Gross Margin | 98.3% |
| Operating Margin | -147.44% |
| Pretax Margin | -155.39% |
| Profit Margin | -155.63% |
| EBITDA Margin | -143.02% |
| EBIT Margin | -147.44% |
| FCF Margin | -133.53% |
